您的当前位置:首页 > 行业数据 > CDK4/6i耐药HR+乳腺癌III期阶段以后在研品种(最高研发阶段开始日期在2023年及以后)
图片属性
图片格式:PNG 图片大小:877KB 图片尺寸:2302*2668
同报告图片
 / 4
CDK4/6i耐药HR+乳腺癌III期阶段以后在研品种(最高研发阶段开始日期在2023年及以后)_第1页
PHRhYmxlIGJvcmRlcj0iMSIgY2VsbHNwYWNpbmc9IjAiIGNlbGxwYWRkaW5nPSI1Ij4KICAgIDx0aGVhZD4KICAgICAgICA8dHIgc3R5bGU9ImJhY2tncm91bmQtY29sb3I6ICNmZjAwMDA7IGNvbG9yOiB3aGl0ZTsiPgogICAgICAgICAgICA8dGg+6I2v5ZOB5ZCN56ewPC90aD4KICAgICAgICAgICAgPHRoPueglOWPkeacuuaehDwvdGg+CiAgICAgICAgICAgIDx0aD7kvZznlKjmnLrliLY8L3RoPgogICAgICAgICAgICA8dGg+6YCC5bqU55eH5YWo55CD5pyA6auY56CU5Y+R6Zi25q615byA5aeL5pel5pyfPC90aD4KICAgICAgICAgICAgPHRoPumAguW6lOeXh+WFqOeQg+acgOmrmOeglOWPkemYtuautTwvdGg+CiAgICAgICAgPC90cj4KICAgIDwvdGhlYWQ+CiAgICA8dGJvZHk+CiAgICAgICAgPHRyPgogICAgICAgICAgICA8dGQ+QXJ2ZWdlc3RyYW50PC90ZD4KICAgICAgICAgICAgPHRkPlBmaXplcjtBcnZpbmFzPC90ZD4KICAgICAgICAgICAgPHRkPkVSIFBST1RBQzwvdGQ+CiAgICAgICAgICAgIDx0ZD4yMDI1LTA2LTA2PC90ZD4KICAgICAgICAgICAgPHRkPueUs+ivt+S4iuW4gjwvdGQ+CiAgICAgICAgPC90cj4KICAgICAgICA8dHI+CiAgICAgICAgICAgIDx0ZD7lkInovr7liKnloZ48L3RkPgogICAgICAgICAgICA8dGQ+V3lldGg7IENlbGN1aXR5PC90ZD4KICAgICAgICAgICAgPHRkPm1UT1LmipHliLbliYI7QWt05oqR5Yi25YmCO1BJM0vmipHliLbliYI8L3RkPgogICAgICAgICAgICA8dGQ+MjAyNS0wOC0yNzwvdGQ+CiAgICAgICAgICAgIDx0ZD7nlLPor7fkuIrluII8L3RkPgogICAgICAgIDwvdHI+CiAgICAgICAgPHRyPgogICAgICAgICAgICA8dGQ+5ZCJ6Zu35Y+4576kPC90ZD4KICAgICAgICAgICAgPHRkPkdlbmVudGVjaCAoUm9jaGUpPC90ZD4KICAgICAgICAgICAgPHRkPumAieaLqeaAp+mbjOa/gOe0oOWPl+S9k+mZjeino+WJgjwvdGQ+CiAgICAgICAgICAgIDx0ZD4yMDI2LTAxLTI5PC90ZD4KICAgICAgICAgICAgPHRkPueUs+ivt+S4iuW4gjwvdGQ+CiAgICAgICAgPC90cj4KICAgICAgICA8dHI+CiAgICAgICAgICAgIDx0ZD50cmFzdHV6dW1hYiBwYW1pcnRlY2FuPC90ZD4KICAgICAgICAgICAgPHRkPuS4ieeUn+WItuiNrztCaW9OVGVjaDvmmKDmgannlJ/niak8L3RkPgogICAgICAgICAgICA8dGQ+YW50aS1IRVIy5oqX5L2T5YG26IGU6I2v54mpPC90ZD4KICAgICAgICAgICAgPHRkPjIwMjMtMDgtMzA8L3RkPgogICAgICAgICAgICA8dGQ+SUlJ5pyf5Li05bqKPC90ZD4KICAgICAgICA8L3RyPgogICAgICAgIDx0cj4KICAgICAgICAgICAgPHRkPnBhbGF6ZXN0cmFudDwvdGQ+CiAgICAgICAgICAgIDx0ZD5PbGVtYSBQaGFybWFjZXV0aWNhbHM8L3RkPgogICAgICAgICAgICA8dGQ+6YCJ5oup5oCn6ZuM5r+A57Sg5Y+X5L2T6ZmN6Kej5YmCPC90ZD4KICAgICAgICAgICAgPHRkPjIwMjMtMDgtMzA8L3RkPgogICAgICAgICAgICA8dGQ+SUlJ5pyf5Li05bqKPC90ZD4KICAgICAgICA8L3RyPgogICAgICAgIDx0cj4KICAgICAgICAgICAgPHRkPuS8puW6t+S+nemahuWmpeWNleaKlzwvdGQ+CiAgICAgICAgICAgIDx0ZD5CcmlzdG9sLU15ZXJzIFNxdWliYjvnmb7liKnlpKnmgZI8L3RkPgogICAgICAgICAgICA8dGQ+RUdGUsOXSEVSM+aKl+S9k+WBtuiBlOiNr+eJqTwvdGQ+CiAgICAgICAgICAgIDx0ZD4yMDI0LTA0LTAzPC90ZD4KICAgICAgICAgICAgPHRkPklJSeacn+S4tOW6ijwvdGQ+CiAgICAgICAgPC90cj4KICAgICAgICA8dHI+CiAgICAgICAgICAgIDx0ZD5TSU0wMjcwPC90ZD4KICAgICAgICAgICAgPHRkPuWFiOWjsOiNr+S4mjwvdGQ+CiAgICAgICAgICAgIDx0ZD7pgInmi6nmgKfpm4zmv4DntKDlj5fkvZPpmY3op6PliYI8L3RkPgogICAgICAgICAgICA8dGQ+MjAyNC0xMS0wNDwvdGQ+CiAgICAgICAgICAgIDx0ZD5JSUnmnJ/kuLTluoo8L3RkPgogICAgICAgIDwvdHI+CiAgICAgICAgPHRyPgogICAgICAgICAgICA8dGQ+em92ZWdhbGlzaWI8L3RkPgogICAgICAgICAgICA8dGQ+UmVsYXkgVGhlcmFwZXV0aWNzO0RFU1JFUzwvdGQ+CiAgICAgICAgICAgIDx0ZD5QSTNLzrEgSDEwNDdY5oqR5Yi25YmCPC90ZD4KICAgICAgICAgICAgPHRkPjIwMjUtMDUtMjE8L3RkPgogICAgICAgICAgICA8dGQ+SUlJ5pyf5Li05bqKPC90ZD4KICAgICAgICA8L3RyPgogICAgICAgIDx0cj4KICAgICAgICAgICAgPHRkPuW+t+W4leabsuWmpeWwpOWNleaKlzwvdGQ+CiAgICAgICAgICAgIDx0ZD5NZXJjayAmIENvLjtEYWlpY2hpIFNhbmt5bzwvdGQ+CiAgICAgICAgICAgIDx0ZD5hbnRpLUhFUjPmipfkvZPlgbbogZToja/niak8L3RkPgogICAgICAgICAgICA8dGQ+MjAyNS0wNy0xMTwvdGQ+CiAgICAgICAgICAgIDx0ZD5JSUnmnJ/kuLTluoo8L3RkPgogICAgICAgIDwvdHI+CiAgICAgICAgPHRyPgogICAgICAgICAgICA8dGQ+cHJpZmV0cmFzdGF0PC90ZD4KICAgICAgICAgICAgPHRkPlBmaXplcjtDYW50aGVyYSBEaXNjb3Zlcnk8L3RkPgogICAgICAgICAgICA8dGQ+S0FUNkHmipHliLbliYI7S0FUNkLmipHliLbliYI8L3RkPgogICAgICAgICAgICA8dGQ+MjAyNS0wNy0xNDwvdGQ+CiAgICAgICAgICAgIDx0ZD5JSUnmnJ/kuLTluoo8L3RkPgogICAgICAgIDwvdHI+CiAgICAgICAgPHRyPgogICAgICAgICAgICA8dGQ+WUwyMDI8L3RkPgogICAgICAgICAgICA8dGQ+QmlvTlRlY2g75a6c6IGU55Sf54mpPC90ZD4KICAgICAgICAgICAgPHRkPmFudGktSEVSM+aKl+S9k+WBtuiBlOiNr+eJqTwvdGQ+CiAgICAgICAgICAgIDx0ZD4yMDI2LTAyLTI4PC90ZD4KICAgICAgICAgICAgPHRkPklJSeacn+S4tOW6ijwvdGQ+CiAgICAgICAgPC90cj4KICAgIDwvdGJvZHk+CjwvdGFibGU+CgrotYTmlpnmnaXmupDvvJrljLvoja/prZTmlrnvvIzkuK3ms7Dor4HliLjnoJTnqbbmiYA=
CDK4/6i耐药HR+乳腺癌III期阶段以后在研品种(最高研发阶段开始日期在2023年及以后)_第2页
CDK4/6i耐药HR+乳腺癌III期阶段以后在研品种(最高研发阶段开始日期在2023年及以后)_第3页
CDK4/6i耐药HR+乳腺癌III期阶段以后在研品种(最高研发阶段开始日期在2023年及以后)_第4页
CDK4/6i耐药HR+乳腺癌III期阶段以后在研品种(最高研发阶段开始日期在2023年及以后)_第5页
所属报告: 康辰药业-603590-A股公司深度报告:主业健康扎实精研创新向星辰-260509(24页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠